The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...

The FDA has started a priority review of Insmed's brensocatib, which is pitching to become the first approved therapy for ...

The FDA accepts and grants priority review to INSM's NDA for brensocatib to treat patients with non-cystic fibrosis bronchiectasis. A decision is due on Aug. 12, 2025.

Patients with bronchiectasis in China have a high disease burden and a low rate of use of evidence-based treatments.

Insmed's promising drug pipeline includes Brensocatib and Arikayce. See why INSM stock is a strong pick with multi-billion ...

BRIDGEWATER, N.J. - Insmed Incorporated (NASDAQ:INSM), a biopharmaceutical company with a market capitalization of $14.57 ...

increased risk of NTM pulmonary disease. The adjusted OR for NTM disease was 15.7 (95% CI 11.4 to 21.5) for COPD, 7.8 (95% CI 5.2 to 11.6) for asthma, 9.8 (95% CI 2.03 to 52.8) for pneumoconiosis, 187 ...

Feb. 6, 2025 — Despite new medication, cystic fibrosis often leads to permanent lung damage. Researchers have discovered that the disease causes changes in the immune system early in life ...

COPD is a progressive, irreversible inflammatory disease of the lungs that makes it difficult to breathe. Cigarette smoking is the most common cause of COPD. Common symptoms include a persistent cough ...

In a report released today, Roy Buchanan from JMP Securities maintained a Buy rating on AN2 Therapeutics, Inc. (ANTX – Research Report), with a ...